Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akshay K Vaishnaw

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Archives of Dermatology|December 17, 2003
Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell countsKenneth B Gordon, Akshay K Vaishnaw, John O'Gorman, et al.
Silence|July 10, 2010
A status report on RNAi therapeuticsAkshay K Vaishnaw, Jared Gollob, Christina Gamba-Vitalo, et al.
Toxicologic Pathology|August 25, 2018
The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute StudiesMaja M Janas, Carole E Harbison, Victoria K Perry, et al.
Antiviral Research|February 5, 2008
Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV)John DeVincenzo, Jeffrey E Cehelsky, Rene Alvarez, et al.
Journal of the American Academy of Dermatology|October 25, 2003
CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized studyAlice B Gottlieb, Thomas B Casale, Ellen Frankel, et al.
Clinical Pharmacology and Therapeutics|June 30, 2020
Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy SubjectsBahru A Habtemariam, Verena Karsten, Husain Attarwala, et al.
Arthritis and Rheumatism|October 18, 2002
Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritisMaarten C Kraan, Arno W R van Kuijk, Huibert J Dinant, et al.
Cardiovascular Drugs and Therapy|June 18, 2020
Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)Daniel P Judge, Arnt V Kristen, Martha Grogan, et al.
Cardiovascular Drugs and Therapy|February 17, 2020
Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)Daniel P Judge, Arnt V Kristen, Martha Grogan, et al.
Nature Communications|July 27, 2022
Rare loss of function variants in the hepatokine gene INHBE protect from abdominal obesityAimee M Deaton, Aditi Dubey, Lucas D Ward, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Archives of Dermatology|December 17, 2003
Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell countsKenneth B Gordon, Akshay K Vaishnaw, John O'Gorman, et al.
Silence|July 10, 2010
A status report on RNAi therapeuticsAkshay K Vaishnaw, Jared Gollob, Christina Gamba-Vitalo, et al.
Toxicologic Pathology|August 25, 2018
The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute StudiesMaja M Janas, Carole E Harbison, Victoria K Perry, et al.
Antiviral Research|February 5, 2008
Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV)John DeVincenzo, Jeffrey E Cehelsky, Rene Alvarez, et al.
Journal of the American Academy of Dermatology|October 25, 2003
CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized studyAlice B Gottlieb, Thomas B Casale, Ellen Frankel, et al.
Clinical Pharmacology and Therapeutics|June 30, 2020
Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy SubjectsBahru A Habtemariam, Verena Karsten, Husain Attarwala, et al.
Arthritis and Rheumatism|October 18, 2002
Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritisMaarten C Kraan, Arno W R van Kuijk, Huibert J Dinant, et al.
Cardiovascular Drugs and Therapy|June 18, 2020
Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)Daniel P Judge, Arnt V Kristen, Martha Grogan, et al.
Cardiovascular Drugs and Therapy|February 17, 2020
Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)Daniel P Judge, Arnt V Kristen, Martha Grogan, et al.
Nature Communications|July 27, 2022
Rare loss of function variants in the hepatokine gene INHBE protect from abdominal obesityAimee M Deaton, Aditi Dubey, Lucas D Ward, et al.
Pageof 2